{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030495","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.639465+00:00","generated_at":"2026-05-31T11:45:21.151938+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Hepion Pharma's interim CEO/CFO resigns; executive chairman takes over","bullets":["John Cavan departed as interim CEO and CFO on August 5, 2024 for personal reasons.","John Brancaccio, executive chairman, appointed interim CEO and CFO effective August 6.","Company is a clinical-stage biotech (HEPA) with no named permanent successor."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030495","json":"https://secwatch.observer/filing/0001493152-24-030495.json","markdown":"https://secwatch.observer/filing/0001493152-24-030495.md","text":"https://secwatch.observer/filing/0001493152-24-030495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/0001493152-24-030495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:45:21.151938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0412849850","claim":"John Brancaccio was appointed as interim Chief Executive Officer and interim Chief Financial Officer at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"On August 6, 2024, John Brancaccio, the Company’s executive chairman was appointed the interim Chief Executive Officer and interim Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/0001493152-24-030495-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer and interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"0b3c12bc0f","claim":"John Cavan departed as interim Chief Executive Officer and Chief Financial Officer at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"On August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the “Company”) left the Company for personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/0001493152-24-030495-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"left"},{"label":"Role","value":"interim Chief Executive Officer and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}